These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3144524)

  • 1. Effect of ciprofloxacin in an in-vitro pharmacokinetic model against Pseudomonas aeruginosa isolated during cystic fibrosis lung infection.
    Stevenson MI; Scott EM; Collier PS
    J Antimicrob Chemother; 1988 Oct; 22(4):491-8. PubMed ID: 3144524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of inhibitory and bactericidal activity of antipseudomonal antibiotics against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Ansorg R; Müller KD; Wiora J
    Chemotherapy; 1990; 36(3):222-9. PubMed ID: 2110878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro bactericidal activity of tobramycin and amikacin alone or in combination against Pseudomonas aeruginosa isolated from patients with cystic fibrosis].
    Bertrou A; Marty N; Henry S; Agueda L; Chabanon G
    Pathol Biol (Paris); 1990 May; 38(5):366-75. PubMed ID: 2114606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of resistance to ciprofloxacin in nutrient-rich and nutrient-limited growth conditions in vitro by Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
    Ferguson MI; Scott EM; Collier PS
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2649-51. PubMed ID: 1810202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis.
    Figueredo VM; Neu HC
    J Antimicrob Chemother; 1988 Jul; 22(1):41-50. PubMed ID: 3139615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of ciprofloxacin and other antibacterial agents against Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients.
    Klinger JD; Aronoff SC
    J Antimicrob Chemother; 1985 Jun; 15(6):679-84. PubMed ID: 3161856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
    Stass H; Delesen H; Nagelschmitz J; Staab D
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to ciprofloxacin of respiratory pathogens in patients with cystic fibrosis.
    Dostal RE; Seale JP; Yan BJ
    Med J Aust; 1992 Jan; 156(1):20-4. PubMed ID: 1734188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro effect of various antibiotics: beta lactams, aminoglycosides and fluoroquinolones alone and in combination against P. aeruginosa isolated from patients with mucoviscidosis].
    Croize J; Gout JP; Robert J; Le Noc P
    Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):573-7. PubMed ID: 2508041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.
    LeBel M; Bergeron MG; Vallée F; Fiset C; Chassé G; Bigonesse P; Rivard G
    Antimicrob Agents Chemother; 1986 Aug; 30(2):260-6. PubMed ID: 3094438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection.
    Dudley MN; Blaser J; Gilbert D; Mayer KH; Zinner SH
    J Infect Dis; 1991 Sep; 164(3):499-506. PubMed ID: 1908000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients.
    Rubio TT; Shapiro C
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():147-52. PubMed ID: 3100490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa.
    Lang BJ; Aaron SD; Ferris W; Hebert PC; MacDonald NE
    Am J Respir Crit Care Med; 2000 Dec; 162(6):2241-5. PubMed ID: 11112146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of the novel ceragenin CSA-13, alone or in combination with colistin, tobramycin, and ciprofloxacin, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
    Bozkurt-Guzel C; Savage PB; Gerceker AA
    Chemotherapy; 2011; 57(6):505-10. PubMed ID: 22286090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-antibiotic effect of ciprofloxacin on Pseudomonas aeruginosa.
    Fuursted K
    Eur J Clin Microbiol; 1987 Jun; 6(3):271-4. PubMed ID: 3113938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
    Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C
    J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.
    Strukova EN; Portnoy YA; Zinner SH; Firsov AA
    J Antimicrob Chemother; 2016 Mar; 71(3):678-84. PubMed ID: 26626718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.